{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:10:06Z","timestamp":1759093806773,"version":"3.44.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ijcard.2021.06.033","type":"journal-article","created":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T10:49:35Z","timestamp":1624099775000},"page":"136-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Vericiguat, organic nitrates, and heart failure in African Americans"],"prefix":"10.1016","volume":"338","author":[{"given":"Onyedika J.","family":"Ilonze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Guglin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ijcard.2021.06.033_bb0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3949\/ccjm.81a.13045","article-title":"Heart failure in African Americans: disparities can be overcome","volume":"81","author":"Sharma","year":"2014","journal-title":"Cleve. Clin. J. Med."},{"issue":"12","key":"10.1016\/j.ijcard.2021.06.033_bb0010","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa0807265","article-title":"Racial differences in incident heart failure among young adults","volume":"360","author":"Bibbins-Domingo","year":"2009","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2021.06.033_bb0015","first-page":"333","article-title":"Representation of blacks, women, and the very elderly (aged > or = 80) in 28 major randomized clinical trials","volume":"9","author":"Hall","year":"1999","journal-title":"Ethn. Dis."},{"issue":"3","key":"10.1016\/j.ijcard.2021.06.033_bb0020","doi-asserted-by":"crossref","first-page":"e212640","DOI":"10.1001\/jamanetworkopen.2021.2640","article-title":"Participation of Black US residents in clinical trials of 24 cardiovascular drugs granted FDA approval, 2006\u20132020","volume":"4","author":"Chen","year":"2021","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/j.ijcard.2021.06.033_bb0025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1071-9164(99)90001-5","article-title":"Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group","volume":"5","author":"Carson","year":"1999","journal-title":"J. Card. Fail."},{"issue":"20","key":"10.1016\/j.ijcard.2021.06.033_bb0030","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2021.06.033_bb0035","doi-asserted-by":"crossref","first-page":"e000214","DOI":"10.1161\/JAHA.113.000214","article-title":"Use of hydralazine-isosorbide dinitrate combination in African American and other race\/ethnic group patients with heart failure and reduced left ventricular ejection fraction","volume":"2","author":"Golwala","year":"2013","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.ijcard.2021.06.033_bb0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ehf2.12421","article-title":"Underuse of hydralazine and isosorbide dinitrate for heart failure in patients of African ancestry: a cross-European survey","volume":"6","author":"Brewster","year":"2019","journal-title":"ESC Heart Fail."},{"issue":"20","key":"10.1016\/j.ijcard.2021.06.033_bb0045","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ijcard.2021.06.033_bb0050","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"New Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ijcard.2021.06.033_bb0055","first-page":"973","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction. Reply","volume":"382","author":"McMurray","year":"2020","journal-title":"New Engl. J. Med."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321010317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321010317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:55:34Z","timestamp":1759092934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527321010317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":11,"alternative-id":["S0167527321010317"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.06.033","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vericiguat, organic nitrates, and heart failure in African Americans","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}